Hightide Therapeutics Inc (HK:2511)
:2511
Want to see HK:2511 full AI Analyst Report?
2511 Stock Chart & Stats
HK$3.05
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.05
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.80 - HK$4.72
Previous CloseN/A
Volume82.00K
Average Volume (3M)1.41M
Market Cap
HK$1.37B
Enterprise ValueHK$1.25B
Total Cash (Recent Filing)HK$502.94M
Total Debt (Recent Filing)HK$126.92M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.80Price Target Upside90.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairThe shift to positive equity and materially improved leverage (debt-to-equity ~0.41 in 2025) is a durable improvement. It reduces near-term solvency risk, expands financing optionality for R&D or partnerships, and lowers the probability of immediate distress-driven dilution over the next several quarters.
Improving Cash Flow TrendA less-negative free cash flow in 2025 versus prior years signals improving operational efficiency or lower cash burn. If sustained, this trend lengthens runway, reduces frequency of dilutive financing needs and supports executing clinical programs over the medium term without immediate capital raises.
Focused Therapeutic NicheSpecialization in metabolic disease creates a clear scientific and commercial focus. A defined therapeutic domain can concentrate talent and R&D spend, facilitate targeted partnerships or licensing, and improve odds of clinical/regulatory progress that can translate to durable competitive advantage if programs advance.
Bears Say
Zero Reported RevenueNo reported revenue across all periods means the company has not yet established commercial validation or organic cash generation. This structural absence of sales makes the business dependent on external funding and increases execution risk until commercialization or licensing creates recurring revenues.
Persistent Cash BurnConsistent negative operating and free cash flow reflects a cash-burning biotech model that requires periodic external funding. Over 2–6 months this elevates funding and dilution risk, can constrain program timelines, and forces prioritization of assets if capital access tightens.
Ongoing Large Losses & Negative ROEPersistently large net losses and negative returns on equity signal an inability to create shareholder value from existing operations. This undermines internal capital formation, increases reliance on external financing, and raises the probability of strategic dilution or reprioritization of programs absent clear near-term revenue catalysts.
Hightide Therapeutics Inc News
2511 FAQ
What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$1.37B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
Hightide Therapeutics Inc’s upcoming earnings report date is Sep 01, 2026 which is in 66 days.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -HK$0.268 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.268.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Undervalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 571,325,700 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.268 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hightide Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.21%
12-Months-Change
Fundamentals
Return on Equity
-39.41%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
2511 Stock 12 Month Forecast
Average Price Target
HK$5.80
▲(90.16% Upside)
Technical Analysis
CANbridge Pharmaceuticals Inc.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Cutia Therapeutics
―
Options Prices
Currently, No data available
---